Evidence map›Paper›PMID 30840336›Full record

Trial reportCancer2019

Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors.

Michelle L Baglia, I-Hsin Lin, Brenda Cartmel, Tara Sanft, Jennifer Ligibel, Dawn L Hershman, Maura Harrigan, Leah M Ferrucci, Fang-Yong Li, Melinda L Irwin

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 14 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 14 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for Integrative Oncology Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors :a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Aerobic exercise and aromatase inhibitor-associated musculoskeletal symptoms: results of a randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Michelle L BagliaFred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0001-8990-4572
I-Hsin LinYale School of Public Health, New Haven, Connecticut.
Brenda CartmelYale School of Public Health, New Haven, Connecticut.
Tara SanftYale Cancer Center, New Haven, Connecticut.
Jennifer LigibelDana-Farber Cancer Institute, Boston, Massachusetts.
Dawn L HershmanHerbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.
Maura HarriganYale School of Public Health, New Haven, Connecticut.
Leah M FerrucciYale School of Public Health, New Haven, Connecticut.
Fang-Yong LiYale School of Public Health, New Haven, Connecticut.
Melinda L IrwinYale School of Public Health, New Haven, Connecticut.
Yale Cancer Center · USColumbia University Irving Medical Center · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USYale New Haven Health System · US

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
RCT of exercise on aromatase inhibitor side effects in breast cancer survivorsR01CA132931 · NCI · YALE UNIVERSITY · PI IRWIN, MELINDA L · 2009 to 2012
$2.4M
NCATS NIH HHS UL1 TR000142NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA132931
6 · The paper itself

Abstract

backgroundThe objective of this study was to evaluate the role of a 12-month exercise intervention on endocrine-related quality of life (QOL) and overall QOL among breast cancer survivors with aromatase inhibitor (AI)-induced arthralgia in the Hormones and Physical Exercise (HOPE) Study.

methodsThis was a randomized controlled trial of 121 breast cancer survivors who were currently receiving AIs and experiencing at least mild arthralgia. QOL was assessed using the Functional Assessment of Cancer Therapy (FACT) questionnaires and the 36-Item Short Form Survey (SF-36) at baseline, 6 months, and 12 months. Participants were randomized to either a 1-year gym-based, supervised exercise intervention group (150 minutes of aerobic exercise and 2 strength-training sessions each week) or a usual care group. Effects of the intervention on QOL were assessed using mixed-model, repeated-measures analysis.

resultsAt 12 months, the exercise group had greater improvement in the overall QOL measures as well as the breast cancer-specific (scores, 2.2 vs 0.7; P = .02), endocrine-specific (scores, 5.6 vs 1.6; P < .001), and fatigue-specific (score, 5.8 vs 0.5; P < .001) subscales compared with the usual care group. The results indicated a stronger effect at 12 months versus 6 months after the intervention.

conclusionsCombined aerobic and resistance exercise, such as treadmill walking and strength training, improved endocrine-related and overall QOL among breast cancer survivors who were experiencing adverse side effects from AIs. Because adverse side effects associated with AI use are quite common and this is the main reason for treatment discontinuation, this nonpharmacologic intervention could benefit many breast cancer survivors and increase successful adherence to AIs in breast cancer treatment.

Indexed as

Quality of LifeAromatase InhibitorsArthralgiaBreast NeoplasmsCancer SurvivorsEndocrine SystemExercise TherapyFemaleFollow-Up StudiesHumansMiddle AgedPatient CompliancePrognosisSurveys and QuestionnairesAromatase Inhibitorsaromatase inhibitorsbreast cancerexercisequality of liferandomized controlled trial

Identifiers

PMID30840336
PMCPMC6731173
OpenAlexW2922261874

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.